Skip to content
10-K

Annual Report

REGENXBIO Inc. RGNX

0001193125-26-094013

← back to feed
Filed
Mar 5, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Feb 27, 2026 51.61M sh
Shares Diluted FY 2025 · Dec 31, 2025 51.57M sh
Shares Diluted FY 2025 · Dec 31, 2024 49.51M sh
Capex FY 2025 · Dec 31, 2025 $2.41M
Capex FY 2025 · Dec 31, 2024 $2.44M
Operating Cash Flow FY 2025 · Dec 31, 2025 −$123.96M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$173.13M
Cash And Equivalents FY 2025 · Dec 31, 2025 $34.47M
Cash And Equivalents FY 2025 · Dec 31, 2024 $57.53M
Stockholders Equity FY 2025 · Dec 31, 2025 $102.73M
Stockholders Equity FY 2025 · Dec 31, 2024 $259.65M
Stockholders Equity FY 2025 · Dec 31, 2023 $311.74M
Current Liabilities FY 2025 · Dec 31, 2025 $118.1M
Current Liabilities FY 2025 · Dec 31, 2024 $103.19M
Total Liabilities FY 2025 · Dec 31, 2025 $350.3M
Total Liabilities FY 2025 · Dec 31, 2024 $206.34M
Current Assets FY 2025 · Dec 31, 2025 $281.28M
Current Assets FY 2025 · Dec 31, 2024 $278M
Total Assets FY 2025 · Dec 31, 2025 $453.03M
Total Assets FY 2025 · Dec 31, 2024 $465.99M
Eps Diluted FY 2025 · Dec 31, 2025 −$3.76
Eps Diluted FY 2025 · Dec 31, 2024 −$4.59
Eps Basic FY 2025 · Dec 31, 2025 −$3.76
Eps Basic FY 2025 · Dec 31, 2024 −$4.59
Sga Expense FY 2025 · Dec 31, 2025 $82.86M
Sga Expense FY 2025 · Dec 31, 2024 $76.62M
Rd Expense FY 2025 · Dec 31, 2025 $228.3M
Rd Expense FY 2025 · Dec 31, 2024 $208.52M
Net Income FY 2025 · Dec 31, 2025 −$193.88M
Net Income FY 2025 · Dec 31, 2024 −$227.1M
Operating Income FY 2025 · Dec 31, 2025 −$161.2M
Operating Income FY 2025 · Dec 31, 2024 −$233.35M
Revenue FY 2025 · Dec 31, 2025 $170.44M
Revenue FY 2025 · Dec 31, 2024 $83.33M